July 20, 2020
NIAID and IAVI, a nonprofit scientific research organization, recently announced a collaboration to develop combinations of HIV broadly neutralizing antibodies that could be produced on a large scale at low cost to prevent and possibly treat HIV. This initiative also will leverage IAVI’s existing partnership with the Serum Institute of India Pvt. Ltd. to develop an affordable and globally accessible antibody-based HIV prevention product.
July 13, 2020
Two new Zika virus studies provide greater detail about how the virus spreads in hosts, with one study offering new therapeutic targets and the other explaining how certain cells protect a fetus from infection.
July 10, 2020
In his final interview with HIV.gov at AIDS 2020: Virtual, NIAID's Dr. Carl Dieffenbach discussed HIV vaccine development, a new partnership to expedite development of HIV antibody combination products, NIH’s engagement in the Ending the HIV Epidemic initiative, and a look to what’s on the horizon in HIV research in the year ahead.
July 09, 2020
Presentations and discussions about the latest HIV research continued at AIDS 2020: Virtual yesterday. HIV.gov shared an interview with Carl Dieffenbach, Ph.D., director of NIAID's Division of AIDS. He discussed additional data from the Tsepamo study on the prevalence of neural tube defects among infants born to women taking the HIV drug dolutegravir at the time of conception, 96-week findings from the South African ADVANCE trial comparing three first-line HIV treatment regimens, and evidence of weight gain caused by different HIV drugs.
July 08, 2020
The 23rd International AIDS Conference (AIDS 2020: Virtual) moved online this year. After the first full day of sessions at which HIV researchers from around the globe shared new scientific findings, HIV.gov spoke about some of the highlights with Carl Dieffenbach, Ph.D., director of the Division of AIDS at NIAID.
June 12, 2020
In a new study published this week in The Lancet, NIAID scientists describe the results of a small Phase 1 trial of a vaccine designed to provide broad protection against mosquito-borne diseases. The trial indicated that the vaccine is safe and induces a strong immune response in healthy volunteers.
June 02, 2020
NIAID researchers found that short-term interruption of HIV treatment with modern antiretroviral therapy (ART) regimens results in similar outcomes compared to historical “analytical treatment interruption” data from participants treated with older ART regimens. Their findings will support future HIV cure studies by updating the control group data to which experimental outcomes are compared.
May 17, 2020
Decades of scientific advances have led to development and implementation of highly effective HIV treatment and prevention tools, strengthening optimism for achieving a durable end to the HIV pandemic. Yet a safe and effective HIV vaccine remains elusive. On HIV Vaccine Awareness Day 2020, NIAID honors the researchers and clinical study participants who play essential roles in advancing HIV vaccine development.
May 15, 2020
Bacterial vaginosis (BV) is inflammation caused by an overgrowth of microorganisms that normally populate a woman’s vagina. In a new study published in The New England Journal of Medicine, NIAID-supported researchers found that applying live beneficial bacteria could safely reduce rates of recurring BV infections.
May 01, 2020
Today, a new NIAID-supported study has begun to track the immune responses of people hospitalized with COVID-19 in 10 research sites across the United States. Data collected in the IMPACC study will help inform recommendations for COVID-19 care and, hopefully, identify new targets and optimal timing for experimental treatments.
April 24, 2020
Today NIAID marks World Malaria Day, acknowledging the profound impact of this ancient, mosquito-borne parasitic disease, which in 2018 sickened 228 million people and killed approximately 405,000 worldwide.
April 17, 2020
Chikungunya, a mosquito-borne disease, has no treatment beyond supportive care, and no vaccine. An experimental chikungunya vaccine has been shown to be both safe and confer durable immune responses in healthy volunteers, researchers report in a paper published this week in The Journal of the American Medical Association (JAMA).
April 13, 2020
The four most common human coronaviruses circulate seasonally, primarily infect children under age 5 and mainly cause mild disease, according to a new University of Michigan study. The scientists hope their eight-year household infection study of the little-known coronaviruses can help colleagues around the world illuminate characteristics about the very different pandemic coronavirus SARS-CoV-2, which causes COVID-19.
April 03, 2020
A candidate vaccine delivered though a thumbnail-sized patch studded with microneedles could help address the coronavirus disease 2019 (COVID-19) pandemic.
April 02, 2020
You might have seen those beautifully colored images of viruses and bacteria in news stories and on the covers of scientific journals – particularly the SARS-CoV-2 images (the virus that causes COVID-19) appearing everywhere. While these images play a major role in the way scientists learn to counteract pathogens and cure disease, that’s not exactly how viruses and bacteria look in our bodies. These images are “colorized” from black-and-white images much like a negative from the old days of film cameras—meaning they are digitally enhanced on a computer. At NIAID, capturing and enhancing these images takes a close collaboration of science and art.
March 24, 2020
Despite more than 100 years of dedicated research, tuberculosis is still the world’s leading cause of death from a single infectious disease. To mark World TB Day this year, we at NIAID again join the world’s public health organizations in declaring that “It’s Time” to consign tuberculosis to the history books by conducting the research needed to end this disease.
March 23, 2020
NIAID has a vision for a modernized, integrated biomedical data ecosystem as outlined in the NIH Strategic Plan for Data Science. To support this goal, it is critical to enhance data-sharing and access and to have NIAID-funded data be findable, accessible, interoperable, and reusable (FAIR).
March 16, 2020
An efficacy trial of an experimental vaccine to protect against many flu virus strains has yielded promising results.
March 06, 2020
The cancer drug paclitaxel and a suppressive regimen of antiretroviral therapy is an effective treatment for AIDS-related Kaposi’s sarcoma, according to researchers who conducted a clinical trial comparing three chemotherapy regimens in combination with antiretroviral therapyin people with advanced AIDS-Kaposi’s sarcoma in Africa and South America.
February 24, 2020
Identifying predictors of autoimmune disease flare-ups could aid treatment for these conditions by allowing doctors to intervene before symptoms worsen. Recognizing immune system attributes that forecast a healthy person’s response to vaccination or infection would help researchers develop new vaccines. A new NIAID study connects these seemingly distinct avenues of research.
Interferon “Fingerprint” Refines Diagnoses of Rare Autoinflammatory Diseases, Identifies Three New Conditions
February 24, 2020
Medicine has recognized rare autoinflammatory diseases for just over 20 years, and while early diagnosis and treatment can improve patient outcomes, similar symptoms across different diseases can make them difficult to diagnose and manage. Now, NIAID scientists and their colleagues have developed an integrated approach that combines next-generation genetic sequencing with advanced diagnostic techniques to characterize inflammatory responses. In doing so, investigators discovered three new autoinflammatory diseases.
February 20, 2020
Each February, NIH observesRare Disease Day to raise awareness about rare diseases, the people they affect, and scientific research. Every day of the year, researchers at NIAID and NIAID-funded institutions collaborate with patients and their families to better understand, diagnose, and treat a spectrum of rare conditions—from immune deficiencies to infectious diseases.
February 19, 2020
NIAID scientists working with investigators from the University of Texas at Austin identified the atomic structure of an important protein on the surface of the novel coronavirus (SARS-CoV-2, formerly called 2019-nCoV). The findings appear in the peer-reviewed journal Science.
February 13, 2020
NIAID has produced images of the novel coronavirus SARS-CoV-2 on its scanning and transmission electron microscopes on Tuesday, Feb. 11, 2020. SARS-CoV-2 causes COVID-2019 disease, which has grown to be a global public health emergency since cases were first detected in Wuhan, China, in December 2019.
February 05, 2020
Somewhere in the genome of Plasmodium falciparum—the microscopic parasite that causes malaria—are instructions for biological machinery that can help this protozoan pest elude the human immune system for years after infection. In a new NIAID Video SNiP, researchers explain their efforts to track down the genetic source of Plasmodium’s stealth.